MUMBAI, India, June 22 -- Intellectual Property India has published a patent application (202641070818 A) filed by Dr. Chandan Mohanty; Dr. Pathakota Roja; Dr. Tapan Kumar Jena; Mrs. Soumya Stuti Patnaik; Mr. Kallem Harsha Vardhan Reddy; Ms. Kanolla Sathwika; Ms. Keerthana Kongari; Ms. Kesagani Tejaswini; and Ms. Khammampati Jyoshna Priya on June 07, 2026, for Sodium Alginate–based Gastroretentive Floating In Situ Gelling System For Sustained Delivery Of Atazanavir Sulphate.
Inventors include Dr. Chandan Mohanty; Dr. Pathakota Roja; Dr. Tapan Kumar Jena; Mrs. Soumya Stuti Patnaik; Mr. Kallem Harsha Vardhan Reddy; Ms. Kanolla Sathwika; Ms. Keerthana Kongari; Ms. Kesagani Tejaswini; and Ms. Khammampati Jyoshna Priya.
The application for the patent was published on June 12, 2026, under issue no. 24/2026.
Abstract: The present invention relates to a sodium alginate–based gastroretentive floating in situ gelling system for sustained delivery of Atazanavir Sulphate. The system addresses the pH-dependent solubility and short biological half-life of Atazanavir Sulphate by prolonging its residence time in the acidic environment of the stomach. The formulation comprises sodium alginate as ion-sensitive polymer, calcium carbonate as cross-linking and gas-generating agent, HPMC K15M as release-retarding polymer, and pharmaceutically acceptable excipients. Upon administration, the formulation undergoes gelation in gastric conditions due to calcium ion-mediated crosslinking and forms a floating gel matrix by entrapment of carbon dioxide. This gel reservoir floats on the gastric contents, prolongs gastric residence time and releases the drug in a sustained, controlled manner over an extended period up to 12 hours. The invention provides an optimized, stable dosage form that enhances drug bioavailability, reduces dosing frequency, and improves patient compliance in antiretroviral therapy.
Disclaimer: Curated by HT Syndication.
